Irritable Bowel Syndrome (IBS) Treatment Market
Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [IBS with Diarrhea (IBS-D), IBS with Constipation (IBSC), and Mixed IBS (IBS-M)], Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
Irritable Bowel Syndrome (IBS) Treatment Market
Current and future Market Scenario
According to our new market research study on “
Irritable Bowel Syndrome (IBS) Treatment Market to 2028 – Global Analysis and Forecast – by Type, Treatment, and End User,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.
Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea.
